T1	location 222 224	US
T2	outcome 1437 1467	12-month progression-free rate
T3	iv-bin-percent 1472 1477	84.1%
T4	cv-bin-percent 1525 1530	79.8%
T5	outcome 1581 1604	12-month survival rates
T6	iv-bin-percent 1610 1615	95.1%
T7	cv-bin-percent 1641 1646	87.9%
T8	total-participants 1321 1324	652
T9	intervention-participants 1335 1338	360
T10	control-participants 1381 1384	292
T14	control 1061 1086	fulvestrant-based therapy
T12	intervention 66 135	palbociclib in combination with an aromatase inhibitor or fulvestrant
T13	eligibility 892 933	patients with confirmed HR+/HER2- ABC/MBC
T11	outcome-Measure 1257 1273	progression-free
T15	outcome-Measure 1278 1292	survival rates
